Safety, tolerability, pharmacodynamic effects and preliminary evidence for efficacy of the anti-hypertension vaccine CYT006-AngQb
Phase of Trial: Phase I/II
Latest Information Update: 20 Aug 2012
At a glance
- Drugs CYT 006 AngQb (Primary)
- Indications Essential hypertension; Hypertension; Various toxicities
- Focus Adverse reactions; Therapeutic Use
- Sponsors Cytos Biotechnology
- 08 Mar 2008 Final results have been published in the Lancet.
- 06 Feb 2007 New trial record.